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ABSTRACT
Cytomegalovirus (CMV) antigenemia is still one of the two major assays available for diagnosis and 
monitoring of  CMV infections. A commercial rapid test recently available in Brazil for quantifi ca-
tion of human cytomegalovirus pp65 antigenemia revealed by immunoﬂ uorescence technique was 
compared with the original in-house method revealed by immunoperoxidase in patients receiving 
solid organ transplants. Of 80 blood samples tested for CMV antigenemia, 34 (42.5%) were positive: 
commercial assay detected 33 (97%) and in-house assay detected 20 (58.8%) samples. The numbers 
of positive cells in the two assays were different, with a median of 4.5 and 12 positive cells obtained by 
in-house and commercial kit, respectively. Discrepancies between assays occurred in 15 specimens 
from patients with low-grade antigenemia (median 6 positive cells). The assay-time was reduced in 
approximately 50% compared to in-house methodology. In conclusion, besides comparable results 
obtained for both assays, the commercial antigenemia assay provides more rapid and sensitive results.
Keywords: cytomegalovirus, antigenemia assay, immmunoperoxidase, immunoﬂ uorescence.
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INTRODUCTION
Cytomegalovirus (CMV) continues to be im-
portant pathogens in immunossupressed indi-
viduals, particularly transplant recipients and 
patients infected with human immunodefi -
ciency virus. In addition to variable CMV clini-
cal presentation, in transplant recipients, CMV 
disease can mimic the symptoms of allograft 
rejection, and differentiation is crucial because 
intensifi cation of immunossupression would 
only aggravate CMV infection.1 
Antiviral therapy can provide signifi cant 
clinical benefi t and be life-saving, provided that 
therapy is initiated promptly. It is therefore es-
sential to have an assay that allows the rapid 
and reliable diagnosis of CMV disease and 
monitoring response to treatment. The CMV 
pp65 antigenemia detect and quantifi es CMV-
infected leukocytes by staining CMV pp65 an-
tigens in peripheral blood. Many studies have 
shown that a positive result is strongly associ-
ated with active CMV infection and disease, 
can be used for monitoring antiviral therapy 
effi cacy and in resistance emergency.2 However, 
the great limitation of this test is that it requires 
approximately 6 hours and is labor-intensive to 
perform. Several modifi cations in the technical 
procedure have been proposed since the initial 
use in the 80s,3 but one-step, erythrocyte lysis 
without neutrophils concentration have dem-
onstrated to save time and simplify the proc-
ess.4 Recently available in Brazil, a commercial 
assay CMV Brite Turbo (IQ Products, Neth-
erlands), with one-step erythrocyte lysis and 
revealed by immunoﬂ uorescence incorporated 
the main advantages of this procedure.
In this study, a rapid commercial Cytome-
galovirus pp65 antigenemia assay, with revela-
tion by immunoﬂ uorescence, was compared to 
an in-house assay, with revelation by immu-
noperoxidase, for detection and quantitation 
of CMV in clinical samples for transplant re-
cipient patients. 
 
MATERIAL AND METHODS
Study samples
Eighty fresh EDTA-anticoagulated blood sam-
ples from consecutive recipients of solid organ 
transplantation were submitted to the Albert 
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Einstein Hospital Microbiology Laboratory for CMV 
pp65 antigenemia evaluation. From each patient, 5 mL of 
blood was used for in-house immunoperoxidase antigen-
emia assay and 1 mL was used for commercial immun-
ofluorescence antigenemia assay. Each slide was evalu-
ated by two well-trained readers independently, and only 
results with up to 10% difference in number of positive 
cells were accepted.
In-house immunoperoxidase revealed CMV anti-
genemia assay
A total of 5 mL of EDTA-anticoagulated blood was mixed 
with 2 mL of 5% dextran solution (Amersham), and the 
mixture was incubated at 37° C for 15 min to allow sedi-
mentation of erythrocytes in 45° angle inclination tube. 
The leukocytes-rich supernatant was mixed with 10 mL 
of phosphated-buffered saline (PBS). After centrifugation 
at 200 g for 5 min, the cell pellet was suspended in 8 mL 
of NH4Cl solution (NH4Cl [8.3 g/L ], KHCO3 [1.0 g/L ], 
EDTA [0.03 g/L ], pH 7.4) on iced water for 10 min at 4° C 
for rupture of the remaining erythrocytes. The cells were 
then washed two times in PBS and centrifuged at 200 g for 
5 min. The fi nal cell pellet was suspended in PBS and con-
centration was adjusted after leukocyte counts obtained 
in T890 cell analyzer (Coulter, USA). Cytospin slides were 
obtained by centrifugation of 3x105 leucocytes on glass 
slides at 500 rpm for 5 min (Cytospin 3; Shandon, USA). 
After slide fi xation with cold acetone for 5 min, each slide 
was covered with 25 µL of 1/10 diluted CMV monoclonal 
mouse antibody clone C10/11 (Dako Cytomation, Den-
mark), and incubated for 45 min at 37° C. After washing 
for 5 min with PBS, the slides were incubated with 25 µL of 
1/100 diluted Horserasch Peroxidase conjugated goat anti-
mouse IgG antibody (Dako Cytomation, Denmark). After 
washing for 5 min with PBS, slides were incubated with 25 
µL of AEC solution (3-amino-9-ethylcarbazole solution in 
0.1M acetate buffer [pH 4.9]) for 10 min at room tempera-
ture in the dark for color development. This coloration was 
stopped with acetate solution for 5 min, and negative leu-
kocytes were stained with Mayer’s Hematoxilin. The total 
numbers of positively stained leukocytes with bright red 
nuclei were counted by light microscopy and results ex-
pressed as the number of pp65-positive/3x105 leukocytes.
Commercial immunoﬂ uorescence revealed CMV 
antigenemia
A total of 1 mL of EDTA-anticoagulated blood was added to 
14 mL of 0.8% NH4Cl solution in a plastic centrifuge tube 
and incubated at 4° C for 15 min. Afterwards, the tube was 
centrifuged 200 g for 3 min and cell pellet washed twice with 
PBS under the same conditions of centrifugation. The fi nal 
cell pellet was suspended in PBS and concentration was ad-
justed after leukocyte counts obtained in T890 cell analyzer 
(Coulter, USA). Cytospin slides were obtained by centrifu-
gation of 4x105 leucocytes on glass slides at 500 rpm for 5 
min (Cytospin 3; Shandon, USA).The slides were air-dried, 
fi xed with 5% formaldehyde, permeabilized with Nonidet 
P-40, and incubated for 20 min at 37° C with 35 µL of pri-
mary monoclonal antibody. After washing for 5 min with 
PBS, slides were incubated with 35 µL of secondary antibody 
ﬂ uorescein isothiocianate-conjugated sheep anti-mouse im-
munoglobulin. At the end, the slides were washed with PBS 
and mounting glycerol and glass. The number of nuclear 
green ﬂ uorescence was scored under epiﬂ uorescence mi-
croscope at 40X magnifi cation and results expressed as the 
number of pp65-positive/4x105 leukocytes.
 
RESULTS
The results are shown in Table 1. Of 80 samples tested, 34 
(42.5%) were positive by either or both CMV antigenemia 
tests. Of these, 19 samples were positive by in-house CMV 
antigenemia assay and commercial CMV antigenemia as-
say, with 20 (55.8%) and 33 (97%) samples detected in 
each assay, respectively. The numbers of positive cells in 
the two assays were different, with a median of 4.5 and 12 
positive cells obtained by in-house and commercial kit, 
respectively. 
Discrepancies between commercial assay and in-house 
developed assay results occurred in 15 specimens from 
patients with low-grade antigenemia. Only one positive 
sample in the in-house assay had two positive cells per 
3x105 leukocytes, and the remaining discordant samples 
had median of 6.5 positive cells per 4x105 leukocytes. The 
difference between assays was obtained in different times 
to complete the assays results: approximately 6 hours 
for in-house assay revealed by immunoperoxidase and 
3 hours for commercial assay revealed by immunofluo-
rescence. Considering as true positive the result obtained 
by any of the tests, commercial CMV antigenemia and 
in-house assays had a sensitivity of 95% and 60%, re-
spectively, with 82.5% of accuracy and 0.62 Kappa index. 
None of the samples showed counts considerable differ-
ent between the two independent readers in any assay. 
Table 1. Comparison of immunofluorescence and 
immunoperoxidase stained CMV antigenemia 
among 80 solid organ transplanted patients
IFI IPO number cell positive count  
   (median)
+ + 19 12/4.5
+ - 14 6.5
- + 1 2
- - 46 0
IFI, indirect immunofluorescence; IPO, immunoperoxidase.
Carraro, Pasternak, Perosa et al.
JUN-2010.indd   323 28/7/2010   10:35:35
324
DISCUSSION
The quality of the stained slides was comparable between 
the two methods, with low nonspecifi c background staining 
and excellent leukocyte morphology. The technical hands-
on time for the commercial CMV antigenemia kit was short-
er and need less blood volume sample. Thus, the availability 
of a commercial assay that can be completed in 3 hours is of 
great benefi t to the laboratory, as well as to patient care. Im-
portantly, the 3-h assay provided quantitative results equiva-
lent to or slightly better than those of the standard test.5 
Besides the reduced testing time, our results according 
to others authors indicate a good correlation between im-
munoperoxidase antigenemia and immunofluorescence 
antigenemia.5,6 Both assays use a mixture of C10-C11 
monoclonal antibodies that react specifically with HCMV 
pp65 proteins giving reaction to different epitopes and 
improving the determination and quantitation of CMV 
antigenemia.7 Clinical significance of specimens found to 
be positive by only one test was not evaluated, but some 
discrepancies in the results produced by both tests was 
probably due to the more than 33% cells that were ap-
plied on slides for rapid testing, as recommended by the 
manufacturer. The justification for the increased number 
of cells is that standard dextran sedimentation for sepa-
ration of leukocytes enriched for neutrophils, the cells 
predominantly express the CMV pp65 antigen in the 
peripheral blood. With direct erythrocyte lysis, there is 
presumably no such enrichment. Therefore, to obtain 
equivalent numbers of neutrophils, a greater number of 
cells must be examined. However, Ho et al.4 reported that 
differential counts of PBLs separated by dextran sedimen-
tation versus direct erythrocyte lysis were, in fact, similar. 
We confirmed this finding. 
Although antigenemia has been replaced by DNAemia 
for diagnosis and preemptive therapy of HCMV infection 
in some transplantation centers, pp65 antigenemia still re-
mains the guiding assay for preemptive therapy in several 
other centers.8 A variety of sophisticated molecular tests are 
now available for CMV. In general, the reagents are more 
expensive, and special equipment and/or separate rooms are 
often required. Because of the time and expense involved 
in performing quantitative nucleic acid detection methods, 
single or even small numbers of samples are usually not 
tested. Rather, samples are batch tested once or several times 
per week. DNA based methods may be advantageous for 
reference laboratories with high test volumes and process-
ing delays due to specimen transportation.9 However, in the 
hospital laboratory, CMV antigenemia has many advantag-
es. None of the molecular tests can provide a quantitative 
result with a 2-h turnaround time. Pp65 CMV antigenemia 
commercial kits have limitations: inﬂ uence of time delayed 
sample processing on cytomegalovirus antigenemia assay 
results in lowest positive cell counts.10-12 and impossibility 
of samples storage,13 besides the possibility that long-term 
storage can be achieved by keeping fi xed slides at -80° C.9
In conclusion, the new commercial CMV antigenemia 
immunoﬂ uorescence revealed to have a good diagnostic 
value and faster assay for the detection and quantifi cation of 
HCMV infection in solid organ transplanted patients. 
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